elafibranor
New PBC Drugs Show Sustained Efficacy in Extension Studies
Elafibranor and seladelpar, both recently approved by the FDA for treatment of PBC, showed prolonged efficacy and ...
MAY 20, 2025
Elafibranor Significantly Improves Prognosis For Patients With PBC, Study Finds
Elafibranor is predicted to increase transplant-free survival and reduce mortality over 15 years in patients with ...
FEBRUARY 13, 2025
FDA Approves Elafibranor for Primary Biliary Cholangitis
The FDA granted accelerated approval for elafibranor (Iqirvo, Ipsen), a peroxisome proliferator−activated ...
JUNE 12, 2024
Load more